Investor Presentation via Investor Meet Company
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, will announce its audited preliminary results for year ended December 31, 2024 (“FY24”) on May 29, 2025.
Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 11:00 BST on the day.
The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor. Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until May 29 09:00 BST, or at any time during the live presentation.
The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.